Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640167 | 0.98 | DRD2 (0.59) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL12605572 | 0.94 | DRD2 (0.59) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL367111 | 0.90 | DRD2 (0.63) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL29423860 | 0.90 | DRD2 (0.63) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL15856591 | 0.85 | OPRM1 (0.47) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL15856596 | 0.85 | OPRM1 (0.46) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL17222487 | 0.85 | OPRM1 (0.47) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL17222489 | 0.85 | OPRM1 (0.47) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL1239171 | 0.81 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL6744630 | 0.81 | DRD2 (0.55) | DRD2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322132-B | N-substituted indole compound and synthesis method thereof | 陕西科技大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-115322132-A | N-substituted indole compound and synthetic method thereof | 陕西科技大学 | 2022-11-11 | — | — | CN | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| EP-2049480-B1 | 2-ARYLINDOLE DERIVATIVES AS mPGES-1 INHIBITORS | ACRAF (IT) | 2013-10-30 | — | — | EP | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| CN-101490000-B | 2-Arylindole derivatives as mPGEs-1 inhibitors | ACRAF | 2012-10-03 | — | — | CN | disclosed |
| CN-101974004-A | Heterocyclic compound and preparation method thereof | UNIV SUZHOU | 2011-02-16 | — | — | CN | disclosed |
| US-20090186922-A1 | 2-ARYLINDOLE DERIVATIVES AS NPGES-I INHIBITORS | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2009-07-23 | — | — | US | disclosed |
| CN-101490000-A | 2-arylindole derivatives as NPGES-1 inhibitors | ACRAF (IT) | 2009-07-22 | — | — | CN | disclosed |
| EP-2049480-A1 | 2-ARYLINDOLE DERIVATIVES AS NPGES-I INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-04-22 | — | — | EP | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| WO-2008006663-A1 | 2-ARYLINDOLE DERIVATIVES AS NPGES-I INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-01-17 | — | — | WO | disclosed |
| EP-0541720-A4 | GOLFOMYCIN DERIVATIVES: NOVEL FUSED RING CYCLODECADIYNE DERIVATIVES | — | 1993-09-01 | — | — | EP | disclosed |
| EP-0541720-A1 | GOLFOMYCIN DERIVATIVES: NOVEL FUSED RING CYCLODECADIYNE DERIVATIVES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002480-A1 | GOLFOMYCIN DERIVATIVES: NOVEL FUSED RING CYCLODECADIYNE DERIVATIVES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0368508-A2 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | DRD2 4809/4885SLC6A4 2364/4885OPRM1 1054/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | DRD2 4809/4885SLC6A4 2364/4885OPRM1 1054/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | DRD2 4809/4885SLC6A4 2364/4885OPRM1 1054/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | DRD2 4809/4885SLC6A4 2364/4885OPRM1 1054/4885 |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | DRD2 4809/4885SLC6A4 2364/4885OPRM1 1054/4885 |
| US-20090186922-A1 | 2-ARYLINDOLE DERIVATIVES AS NPGES-I INHIBITORS | PTGES, NAT1, CSNK1G2 | DRD2 466/4885SLC6A4 2059/4885OPRM1 80/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | DRD2 381/4885SLC6A4 527/4885OPRM1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.